Core Viewpoint - The company plans to sign a lease agreement with Tianjin Tai Ping Pharmaceutical Co., Ltd. to rent out a warehouse for three years, aiming to improve asset utilization and generate stable rental income [1][10]. Summary by Sections 1. Overview of the Related Transaction - The company intends to lease a property located at No. 5 Tengda Road, Beichen District, Tianjin, with a usage area of 24,112.59 square meters to Tianjin Tai Ping Pharmaceutical Co., Ltd. for a total contract amount of 14.7858 million RMB, which accounts for 0.19% of the company's latest audited net assets [1][2]. 2. Basic Information of the Related Party - Tianjin Tai Ping Pharmaceutical Co., Ltd. is a subsidiary of the company's controlling shareholder, Tianjin Pharmaceutical Group Co., Ltd., which holds 56.65% of its shares, while the company holds 43.35% [4][11]. 3. Financial Impact and Transaction Details - The lease agreement is based on fair market pricing and is expected to positively impact the company's financial status and operational results, aligning with the interests of the company and all shareholders [10][11]. 4. Approval Process - The board of directors approved the lease agreement, with related directors abstaining from voting. The remaining five non-related directors and all independent directors consented to the proposal [10][11]. 5. Historical Related Transactions - In the past 12 months, the company has engaged in related transactions with the same related party, totaling 17.3275 million RMB, which is 0.22% of the latest audited net assets [2][11].

Group 1 - The core index of the China Securities Index for Food and Major Consumer Goods Retail has shown a decline of 2.40% over the past month, 6.58% over the past three months, and 6.48% year-to-date [1] - The index is composed of listed companies in the food and drug retail sector, reflecting the overall performance of these companies, with a base date of December 31, 2004, set at 1000.0 points [1] - The top ten weighted companies in the index include Yonghui Supermarket (6.61%), Digital China (6.21%), Wancheng Group (4.68%), Shanghai Pharmaceuticals (4.41%), Yifeng Pharmacy (4.32%), Jiuzhoutong (3.86%), Kidswant (3.41%), Sinopharm (3.25%), Wangfujing (3.17%), and TianKang (3.09%) [1] Group 2 - The market segments represented in the index include 43.94% in pharmaceutical commerce, 21.32% in supermarkets and convenience stores, 20.29% in specialty retail, and 14.46% in department stores [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

每经记者｜王琳 每经编辑｜董兴生 6月18日晚间，重药控股（000950.SZ，股价4.94元，市值85.37亿元）发布公告披露，其于6月18日收到公司控股股东重庆医药健康产业有限公司（以下简称 重庆医健）的告知函，获悉其股权结构拟发生变更。 具体来说，重庆医健的股东重庆渝富控股集团有限公司（以下简称重庆渝富）于6月18日在重庆联合产权交易所集团股份有限公司（以下简称重庆联交所） 公开挂牌转让重庆医健24%股权。 2024年全年，重庆医健实现营业收入和净利润分别为811.75亿元和4.14亿元；2025年第一季度，重庆医健的营业收入和净利润分别为207.57亿元和1.87亿元。 截至2025年一季度末，重庆医健的所有者权益为188.07亿元。 | | 以下数据出自年度审计报告 | | | | --- | --- | --- | --- | | 2024 (年度) | 营业收入 | 营业利润 | 浄利润 | | | 8117500. 21万元 | 57886. 30万元 | 41361. 24万元 | | | 资产总计 | 负债总计 | 所有者权益 | | | 6900556. 26万元 | 5042140.1 ...

Core Viewpoint - The article outlines the management measures for the employee stock ownership plan (ESOP) of Jiuzhoutong Pharmaceutical Group Co., Ltd. for the period 2023-2026, emphasizing compliance, voluntary participation, and risk-bearing principles. Group 1: General Principles - The ESOP will be implemented in strict accordance with relevant laws and regulations, ensuring accurate and timely information disclosure [1][2] - Participation in the ESOP is voluntary, with no forced allocation or distribution to employees [2] Group 2: Plan Implementation Procedures - The company will solicit employee opinions through representative meetings before implementing the ESOP [3] - The board of directors must approve the ESOP draft and ensure that related directors abstain from voting [3][4] - A legal opinion will be obtained before the shareholders' meeting to review the ESOP [4] - The shareholders' meeting will vote on the ESOP using a combination of on-site and online voting methods [4] Group 3: Funding and Stock Sources - The total amount of funds to be raised for the ESOP is approximately 461.69 million yuan, with each share priced at 1 yuan [5] - The ESOP will acquire stocks from the company's repurchase account and through market purchases [5] - The total scale of the ESOP is planned to be around 48.60 million shares, accounting for approximately 2.59% of the company's total share capital [5] Group 4: Lock-up Period and Performance Assessment - The lock-up period for the ESOP shares is set at 12 months from the distribution date of each batch [6][7] - Performance assessments will determine the returns for participants based on individual performance ratings [7] Group 5: Management Structure - The ESOP will be managed by a management committee elected by the participants, which will oversee daily operations and asset management [8][9] - The management committee is responsible for making decisions regarding the sale and distribution of the ESOP's assets [9] Group 6: Rights and Obligations of Participants - Participants have the right to request cash distributions or stock transfers after the lock-up period [14] - Participants are obligated to comply with the management committee's decisions regarding the ESOP [14][15]

第二条 九州通医药集团股份有限公司（以下简称"公司"）系依照《公司 法》和其他有关规定成立的股份有限公司。 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）和其他有关规定，制定本章程。 公司经湖北省商务厅（鄂商资【2008】133 号文）批准，在九州通集团有限 责任公司的基础上以整体变更方式发起设立。公司在湖北省市场监督管理局注册 登记，取得营业执照，统一社会信用代码为 9142000071451795XA。 第三条 公司于【2010 年 10 月 14 日】经中国证券监督管理委员会（以下简 称"中国证监会"）核准，首次向社会公众发行人民币普通股【150,000,000】股， 于【2010 年 11 月 2 日】在【上海证券交易所】上市。 公司于【2024 年 7 月 5 日】经中国证监会核准，公司向特定对象发行优先 九州通医药集团股份有限公司 章程 （2025 年 6 月修订） 目 录 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三 ...

| 北京海润天睿律师事务所 | | --- | | 关于九州通医药集团股份有限公司 | | 修订 2023-2025 年员工持股计划（草案）及第三批分 | | 配的 | | 法律意见书 | | 中国·北京 | | 朝阳区建外大街甲 14 号广播大厦 17 层 邮政编码：100022 | | 电话：(010)65219696 传真:(010)88381869 | | 二〇二五年六月 | | 释义 | | 在本法律意见书中，除非文义另有所指，下列词语具有下述含义： | | 九州通、公司 指 九州通医药集团股份有限公司 | | 《九州通医药集团股份有限公司 2023-2025 年员工持股 | | 《员工持股计划（草案）》 指 | | 计划（草案）》 | | 《员工持股计划（草案修 《九州通医药集团股份有限公司 2023-2026 年员工持股 | | 指 | | 订稿）》 计划（草案）（修订稿）》 | | 2023-2025 九州通医药集团股份有限公司 年员工持股计 | | 本次员工持股计划 指 划（本次名称拟修订为九州通医药集团股份有限公司 | | 九州通医药集团股份有限公司拟修订 2023-2025 年员工 | ...

证券代码：600998 证券简称：九州通 九州通医药集团股份有限公司 （草案）（修订稿） 九州通医药集团股份有限公司 二○二五年六月 一、九州通医药集团股份有限公司（以下简称"九州通"或"公司"）2023-2026 年员工持股计划（以下简称"本员工持股计划"）须经公司股东会批准后方可实 施，本员工持股计划能否获得公司股东会批准，存在不确定性； 二、本员工持股计划设立后将由公司自行管理，也可根据实际需要聘请外部 专业机构为本员工持股计划提供资产管理、咨询等服务；但能否达到计划规模、 目标存在不确定性； 三、有关本员工持股计划的具体的资金来源、出资金额、实施方案等属初步 结果，能否完成实施，存在不确定性； 四、若员工认购资金较低时，本员工持股计划存在不成立的风险； 五、股票价格受公司经营业绩、宏观经济周期、国际/国内政治经济形势及 投资者心理等多种复杂因素影响。因此，股票交易是有一定风险的投资活动，投 资者对此应有充分准备； 六、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 -2- 特别提示 声 明 本公司及公司董事会全体成员保证本员工持股计划不存在虚假记载、误导性 陈述或重大遗漏 ...

Summary of Huadong Medicine Conference Call Company Overview - Huadong Medicine is a leading enterprise in the pharmaceutical industry, with a strong channel advantage, particularly in the metabolic and autoimmune fields. The company was established in 1993 and listed on the Shenzhen Stock Exchange in 2000. Its business encompasses pharmaceutical manufacturing, commercial operations, and medical aesthetics, with pharmaceutical manufacturing being the largest segment. In 2024, the company expects industrial revenue of approximately 14 billion yuan, commercial revenue of about 28 billion yuan, and medical aesthetics revenue of around 2 billion yuan [3][4][7]. Financial Performance - In 2024, Huadong Medicine's total revenue is projected to exceed 40 billion yuan, representing a year-on-year growth of 3%. The net profit attributable to shareholders is expected to grow by over 20%, benefiting from business transformation and the clearance of negative factors [2][4]. Innovation and Product Pipeline - The company is actively developing innovative drugs in the fields of diabetes, weight loss, autoimmune diseases, and oncology. The first domestic generic version of Liraglutide has been approved, with Semaglutide and other products expected to be approved soon. The company is also developing multi-target GLP-1 products such as HDM1,002 and HDM1,005, which are anticipated to quickly capture market share [2][6][14]. Commercial Operations - The commercial segment, primarily located in Zhejiang Province, is expected to generate over 28 billion yuan in revenue in 2024, a 3% increase year-on-year. The company has restored stable profitability through innovative development and has a competitive advantage in market access and network coverage, which synergizes well with its industrial operations [2][7][23]. Medical Aesthetics - The medical aesthetics segment has seen significant success, with the "Girl Needle" product achieving over 1 billion yuan in sales. The company also offers hyaluronic acid and energy source devices, with expectations for double-digit growth in 2025. The acquisition of UK-based Sinclair has facilitated global expansion [8][9][20]. Risks and Challenges - Key risks include potential delays in innovative product development, intensified market competition, and lower-than-expected sales of core products. These factors could impact future performance and require ongoing monitoring and strategic adjustments [10]. ADC and Oncology Developments - Huadong Medicine has made substantial innovations in the ADC (Antibody-Drug Conjugate) field, with significant products like HDM1,022 and HDM1,005 targeting advanced malignancies. The company is also collaborating with other firms to develop CAR-T therapies, which are expected to contribute to revenue growth [15][16][17]. Industrial Microbiology - The industrial microbiology segment has maintained rapid growth of 30%-40% in recent years, contributing significantly to revenue. The company has over 40 years of experience in this field, with leading subsidiaries in the industry. Industrial microbiology revenue is expected to exceed 700 million yuan in 2024, reflecting a 40% year-on-year increase [21][22]. Valuation and Future Outlook - The current market capitalization of Huadong Medicine is over 70 billion yuan, with projected profits for 2025 estimated between 3.9 billion and 4 billion yuan, resulting in a price-to-earnings ratio of less than 20 times. This valuation is considered low given the company's innovative transformation and traditional channel advantages. The company has multiple core innovation pipelines in autoimmune, endocrine, and oncology fields, which are expected to enhance market recognition through potential overseas licensing agreements [24].

Core Viewpoint - The company has approved a profit distribution plan for the fiscal year 2024, which includes a cash dividend of RMB 3.66 per 10 shares, totaling RMB 203.7 million to be distributed to shareholders [1][5][3]. Group 1: Profit Distribution Plan - The profit distribution plan was approved at the annual shareholders' meeting held on June 10, 2025, based on a total share capital of 556,565,077 shares [1][2]. - The total cash dividend to be distributed amounts to RMB 203,702,818.18, with no stock dividends or capital reserve transfers [1][5]. - The cash dividend will be distributed to all shareholders, with specific tax implications based on the type of shares held [5][6]. Group 2: Dividend Payment Details - The cash dividend of RMB 3.66 per 10 shares is inclusive of tax, with different tax treatments for various types of shareholders [5][6]. - The A-share equity registration date is set for June 24, 2025, and the ex-dividend date is June 25, 2025 [7]. - B-share shareholders will have their last trading day on June 24, 2025, with the same ex-dividend date of June 25, 2025 [7][8]. Group 3: Distribution Method - The cash dividends for A-share shareholders will be directly credited to their accounts through their custodial securities companies on June 25, 2025 [9]. - B-share dividends will be credited on June 27, 2025, with specific instructions for shareholders who may need to handle tax-related issues [9][10]. - The company will bear all legal responsibilities for any discrepancies in the dividend distribution process [9].

今天A股缩量上涨，总成交额 1.24万亿元，相比前一个交易日明显缩量。 上周五的地缘风险对市场造成 了较大影响，但今天全球市场情绪已开始恢复。目前A股正处于关键点位，面临技术面压力，本周料指 数大概率维持震荡整理格局，但市场中期向好逻辑未变，短线可多关注防御性板块。 | 英国富时100 | 法国CAC40 | 德国DAX | | --- | --- | --- | | 8890.68 | 7752.89 | 23619.71 | | +40.05 +0.45% | +68.21 +0.89% | +103.48 +0.44% | | 意大利MIB | 俄罗斯MOEX | 欧洲STOXX50 | | 39855.08 | 2757.23 | 5329.30 | | +416.33 +1.06% | +6.91 +0.25% | +38.83 +0.73% | | 亚太市场 | | | | 日经225 | 韩国综合 | 新加坡海峡 | | 38311.33 | 2946.6600 | 3908.46 | | +477.08 +1.26% +52.0400 +1.80% | | -2.96 -0.08% | | 澳 ...